{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:13:02Z","timestamp":1792872782517,"version":"4.5.0"},"reference-count":93,"publisher":"Walter de Gruyter GmbH","issue":"9","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Neurofilament light chain (NfL) has been identified as a sensitive and broadly validated biomarker of neuroaxonal injury across multiple neurological conditions, including multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Alzheimer\u2019s disease (AD), and atypical parkinsonian syndromes. This position paper provides a multidisciplinary roadmap for translating circulating NfL testing into routine clinical practice, integrating analytical, interpretative, and organizational dimensions. It summarizes the biological basis and clinical evidence supporting NfL as a diagnostic, prognostic, and monitoring tool, emphasizing its high sensitivity to neuroaxonal injury across both acute inflammatory and chronic degenerative processes. Comparative analysis of immunoassay technologies identifies strengths and critical sources of variability, while operational guidelines highlight the need for pre-analytical standardization, inter-laboratory harmonization, and participation in quality control schemes. Confounders such as age, BMI, renal function, and comorbidities are shown to significantly influence interpretation, supporting the use of age-adjusted Z-scores, percentiles, and longitudinal normalization for accurate patient-level evaluation. From a clinical standpoint, the paper focuses on practical indications for NfL testing in MS, recommending its use for disease activity prediction and monitoring, treatment decisions and treatment response assessment. Integration of blood NfL with magnetic resonance imaging (MRI), glial fibrillary acidic protein (GFAP) and other biomarkers measurement is proposed as a core strategy for biomarker-driven precision neurology. The authors outline an implementation model encompassing laboratory validation, structured reporting and alignment with national neurological care pathways. They conclude that the transition of NfL into clinical use requires harmonized analytical procedures, interdisciplinary education, and sustainable governance frameworks. Priority actions include regulatory qualification, establishment of international reference materials, and development of pragmatic real-world trials to consolidate its clinical utility. When these measures are achieved, NfL will represent a cornerstone biomarker for precision neurology and neurodegeneration monitoring.<\/jats:p>","DOI":"10.1515\/cclm-2025-1743","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T21:44:22Z","timestamp":1773524662000},"page":"1904-1918","source":"Crossref","is-referenced-by-count":4,"title":["Translating neurofilament light chain testing into clinical practice: a multidisciplinary implementation roadmap"],"prefix":"10.1515","volume":"64","author":[{"given":"Roberto","family":"Furlan","sequence":"first","affiliation":[{"name":"Vita-Salute San Raffaele University , Milan , Italy"},{"name":"Institute of Experimental Neurology, Division of Neuroscience , IRCCS Ospedale San Raffaele , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Di Sapio","sequence":"additional","affiliation":[{"name":"Regional Referral Multiple Sclerosis Centre, Department of Neurology , University Hospital San Luigi Gonzaga , Orbassano , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Ferraro","sequence":"additional","affiliation":[{"name":"Department of Neuroscience , Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria di Modena , Emilia-Romagna , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rossi","sequence":"additional","affiliation":[{"name":"Vita-Salute San Raffaele University , Milan , Italy"},{"name":"Institute of Experimental Neurology, Division of Neuroscience , IRCCS Ospedale San Raffaele , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Valentino","sequence":"additional","affiliation":[{"name":"Regional Referral Multiple Sclerosis Centre, Department of Neurology , University Hospital San Luigi Gonzaga , Orbassano , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4296-429X","authenticated-orcid":false,"given":"Daniela","family":"Terracciano","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences , University of Naples Federico II , Naples , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"2026091512595688619_j_cclm-2025-1743_ref_001","doi-asserted-by":"crossref","unstructured":"Delaby, C, Ladang, A, Martinez-Yriarte, J, Zecca, C, Logroscino, G, Kortvelyessy, P, et al.. Clinical use and reporting of neurofilament quantification in neurological disorders: a global overview. Alzheimer\u2019s Dement 2025;21:e70343. https:\/\/doi.org\/10.1002\/alz.70343.","DOI":"10.1002\/alz.70343"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_002","doi-asserted-by":"crossref","unstructured":"Mullard, A. NfL makes regulatory debut as neurodegenerative disease biomarker. Nat Rev Drug Discov 2023;22:431\u20134. https:\/\/doi.org\/10.1038\/d41573-023-00083-z.","DOI":"10.1038\/d41573-023-00083-z"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_003","doi-asserted-by":"crossref","unstructured":"Khalil, M, Teunissen, CE, Lehmann, S, Otto, M, Piehl, F, Ziemssen, T, et al.. Neurofilaments as biomarkers in neurological disorders\u00a0\u2013\u00a0towards clinical application. Nat Rev Neurol 2024;20:269\u201387. https:\/\/doi.org\/10.1038\/s41582-024-00955-x.","DOI":"10.1038\/s41582-024-00955-x"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_004","doi-asserted-by":"crossref","unstructured":"Nicolella, V, Fiorenza, M, Monteiro, I, Novarella, F, Sirica, R, D\u2019Angelo, M, et al.. Clinical utility of the Lumipulse immunoassay for plasma neurofilament light chain in multiple sclerosis. J\u00a0Neurol Sci 2024;463:123115. https:\/\/doi.org\/10.1016\/j.jns.2024.123115.","DOI":"10.1016\/j.jns.2024.123115"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_005","doi-asserted-by":"crossref","unstructured":"Rosen, C, Mitre, B, Nellgard, B, Axelsson, M, Constantinescu, R, Andersen, PM, et al.. High levels of neurofilament light and YKL-40 in cerebrospinal fluid are related to poor outcome in ALS. J\u00a0Neurol Sci 2024;463:123112. https:\/\/doi.org\/10.1016\/j.jns.2024.123112.","DOI":"10.1016\/j.jns.2024.123112"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_006","doi-asserted-by":"crossref","unstructured":"Bamford, AR, Parkin, GM, Corey-Bloom, J, Thomas, EA. Comparisons of neurodegenerative disease biomarkers across different biological fluids from patients with Huntington\u2019s disease. J\u00a0Neurol 2025;272:158. https:\/\/doi.org\/10.1007\/s00415-024-12785-4.","DOI":"10.1007\/s00415-024-12785-4"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_007","doi-asserted-by":"crossref","unstructured":"Lee, JS, Kang, JH, Kang, CH, Kim, JG, Seo, SW, Park, YH, et al.. Longitudinal measurement of serum neurofilament light chain in patients with CADASIL. J\u00a0Stroke 2025;27:261\u20135. https:\/\/doi.org\/10.5853\/jos.2024.05666.","DOI":"10.5853\/jos.2024.05666"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_008","doi-asserted-by":"crossref","unstructured":"La Civita, E, Nicolella, V, Fiorenza, M, Cosimato, V, Castaldo, G, Morra, VB, et al.. Advancing clinical use of neurofilament light chain: translational insights from research to routine practice. Biomark Insights 2025;20:11772719251364018. https:\/\/doi.org\/10.1177\/11772719251364018.","DOI":"10.1177\/11772719251364018"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_009","doi-asserted-by":"crossref","unstructured":"Chitnis, T, Magliozzi, R, Abdelhak, A, Kuhle, J, Leppert, D, Bielekova, B. Blood and CSF biomarkers for multiple sclerosis: emerging clinical applications. Lancet Neurol 2025;12:1066\u201378. https:\/\/doi.org\/10.1016\/S1474-4422(25)00249-2.","DOI":"10.1016\/S1474-4422(25)00249-2"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_010","doi-asserted-by":"crossref","unstructured":"Bar-Or, A, Nicholas, J, Feng, J, Sorrell, F, Cascione, M. Exploring the clinical utility of neurofilament light chain assays in multiple sclerosis management. Neurol Neuroimmunol Neuroinflamm 2025;12:e200427. https:\/\/doi.org\/10.1212\/nxi.0000000000200427.","DOI":"10.1212\/NXI.0000000000200427"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_011","doi-asserted-by":"crossref","unstructured":"Khalil, M, Teunissen, CE, Otto, M, Piehl, F, Sormani, MP, Gattringer, T, et al.. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 2018;14:577\u201389. https:\/\/doi.org\/10.1038\/s41582-018-0058-z.","DOI":"10.1038\/s41582-018-0058-z"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_012","doi-asserted-by":"crossref","unstructured":"Shaw, G, Madorsky, I, Li, Y, Wang, Y, Jorgensen, M, Rana, S, et al.. Uman-type neurofilament light antibodies are effective reagents for the imaging of neurodegeneration. Brain Commun 2023;5:fcad067. https:\/\/doi.org\/10.1093\/braincomms\/fcad067.","DOI":"10.1093\/braincomms\/fcad067"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_013","doi-asserted-by":"crossref","unstructured":"Llaurado, A, Garcia-Carmona, C, Restrepo-Vera, JL, Aleman, J, Salvado, M, Sanchez-Tejerina, D, et al.. Usefulness of serum neurofilament light chain in chronic inflammatory demyelinating polyradiculoneuropathy. J\u00a0Neurol Sci 2025;470:123397. https:\/\/doi.org\/10.1016\/j.jns.2025.123397.","DOI":"10.1016\/j.jns.2025.123397"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_014","doi-asserted-by":"crossref","unstructured":"Lu, CH, Macdonald-Wallis, C, Gray, E, Pearce, N, Petzold, A, Norgren, N, et al.. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology 2015;84:2247\u201357. https:\/\/doi.org\/10.1212\/wnl.0000000000001642.","DOI":"10.1212\/WNL.0000000000001642"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_015","doi-asserted-by":"crossref","unstructured":"Mattsson, N, Andreasson, U, Zetterberg, H, Blennow, K. Alzheimer\u2019s disease neuroimaging I. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol 2017;74:557\u201366. https:\/\/doi.org\/10.1001\/jamaneurol.2016.6117.","DOI":"10.1001\/jamaneurol.2016.6117"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_016","doi-asserted-by":"crossref","unstructured":"Yuan, A, Rao, MV, Veeranna Nixon, RA. Neurofilaments and neurofilament proteins in health and disease. Cold Spring Harbor Perspect Biol 2017;9. https:\/\/doi.org\/10.1101\/cshperspect.a018309.","DOI":"10.1101\/cshperspect.a018309"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_017","doi-asserted-by":"crossref","unstructured":"Millecamps, S, Gowing, G, Corti, O, Mallet, J, Julien, JP. Conditional NF-L transgene expression in mice for in\u00a0vivo analysis of turnover and transport rate of neurofilaments. J\u00a0Neurosci 2007;27:4947\u201356. https:\/\/doi.org\/10.1523\/jneurosci.5299-06.2007.","DOI":"10.1523\/JNEUROSCI.5299-06.2007"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_018","doi-asserted-by":"crossref","unstructured":"O\u2019Connell, GC, Alder, ML, Smothers, CG, Still, CH, Webel, AR, Moore, SM. Diagnosis of ischemic stroke using circulating levels of brain-specific proteins measured via high-sensitivity digital ELISA. Brain Res 2020;1739:146861. https:\/\/doi.org\/10.1016\/j.brainres.2020.146861.","DOI":"10.1016\/j.brainres.2020.146861"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_019","doi-asserted-by":"crossref","unstructured":"Mortensen, C, Steffensen, KD, Simonsen, E, Herskind, K, Madsen, JS, Olsen, DA, et al.. Neurofilament light chain as a biomarker of axonal damage in sensory neurons and paclitaxel-induced peripheral neuropathy in patients with ovarian cancer. Pain 2023;164:1502\u201311. https:\/\/doi.org\/10.1097\/j.pain.0000000000002840.","DOI":"10.1097\/j.pain.0000000000002840"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_020","doi-asserted-by":"crossref","unstructured":"Shahim, P, Politis, A, van der Merwe, A, Moore, B, Chou, YY, Pham, DL, et al.. Neurofilament light as a biomarker in traumatic brain injury. Neurology 2020;95:e610\u201322. https:\/\/doi.org\/10.1212\/wnl.0000000000009983.","DOI":"10.1212\/WNL.0000000000009983"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_021","doi-asserted-by":"crossref","unstructured":"Obara, K, Ito, D, Nilsson, C, Janelidze, S, Santillo, A, Katsuno, M, et al.. Diagnostic and prognostic value of blood and cerebrospinal fluid biomarkers in amyotrophic lateral sclerosis: a systematic review and meta-analysis. Eur J Neurol 2025;32:e70382. https:\/\/doi.org\/10.1111\/ene.70382.","DOI":"10.1111\/ene.70382"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_022","doi-asserted-by":"crossref","unstructured":"Miller, T, Cudkowicz, M, Shaw, PJ, Andersen, PM, Atassi, N, Bucelli, RC, et al.. Phase 1\u20132 trial of antisense oligonucleotide tofersen for SOD1 ALS. N\u00a0Engl J Med 2020;383:109\u201319. https:\/\/doi.org\/10.1056\/nejmoa2003715.","DOI":"10.1056\/NEJMoa2003715"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_023","doi-asserted-by":"crossref","unstructured":"Thomas, K, Spin, P, Sir, N, Hou, K, Ashton, NJ, Zetterberg, H, et al.. Neurofilament light (NfL) chain levels predict clinical decline in Alzheimer\u2019s disease: a systematic review and meta-analysis. J\u00a0Alzheimers Dis Rep 2025;9:25424823251379878. https:\/\/doi.org\/10.1177\/25424823251379878.","DOI":"10.1177\/25424823251379878"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_024","doi-asserted-by":"crossref","unstructured":"Pontecorvo, MJ, Lu, M, Burnham, SC, Schade, AE, Dage, JL, Shcherbinin, S, et al.. Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial. JAMA Neurol 2022;79:1250\u20139. https:\/\/doi.org\/10.1001\/jamaneurol.2022.3392.","DOI":"10.1001\/jamaneurol.2022.3392"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_025","doi-asserted-by":"crossref","unstructured":"Kou, W, Li, S, Yan, R, Zhang, J, Wan, Z, Feng, T. Cerebrospinal fluid and blood neurofilament light chain in Parkinson\u2019s disease and atypical parkinsonian syndromes: a systematic review and Bayesian network meta-analysis. J\u00a0Neurol 2025;272:311. https:\/\/doi.org\/10.1007\/s00415-025-13051-x.","DOI":"10.1007\/s00415-025-13051-x"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_026","doi-asserted-by":"crossref","unstructured":"Centonze, D, Di Sapio, A, Brescia Morra, V, Colombo, E, Inglese, M, Paolicelli, D, et al.. Steps toward the implementation of neurofilaments in multiple sclerosis: patient profiles to be prioritized in clinical practice. Front Neurol 2025;16:1571605. https:\/\/doi.org\/10.3389\/fneur.2025.1571605.","DOI":"10.3389\/fneur.2025.1571605"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_027","doi-asserted-by":"crossref","unstructured":"Bittner, S, Oh, J, Havrdova, EK, Tintore, M, Zipp, F. The potential of serum neurofilament as biomarker for multiple sclerosis. Brain 2021;144:2954\u201363. https:\/\/doi.org\/10.1093\/brain\/awab241.","DOI":"10.1093\/brain\/awab241"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_028","doi-asserted-by":"crossref","unstructured":"van Lierop, ZY, Wessels, MH, Lekranty, WM, Moraal, B, Hof, SN, Hogenboom, L, et al.. Impact of serum neurofilament light on clinical decisions in a tertiary multiple sclerosis clinic. Mult Scler 2024;30:1620\u20139. https:\/\/doi.org\/10.1177\/13524585241277044.","DOI":"10.1177\/13524585241277044"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_029","doi-asserted-by":"crossref","unstructured":"Wilson, DH, Rissin, DM, Kan, CW, Fournier, DR, Piech, T, Campbell, TG, et al.. The simoa HD-1 analyzer: a novel fully automated digital immunoassay analyzer with single-molecule sensitivity and multiplexing. J\u00a0Lab Autom 2016;21:533\u201347. https:\/\/doi.org\/10.1177\/2211068215589580.","DOI":"10.1177\/2211068215589580"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_030","doi-asserted-by":"crossref","unstructured":"Rosengren, LE, Karlsson, JE, Karlsson, JO, Persson, LI, Wikkelso, C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J\u00a0Neurochem 1996;67:2013\u20138. https:\/\/doi.org\/10.1046\/j.1471-4159.1996.67052013.x.","DOI":"10.1046\/j.1471-4159.1996.67052013.x"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_031","doi-asserted-by":"crossref","unstructured":"Bridel, C, van Wieringen, WN, Zetterberg, H, Tijms, BM, Teunissen, CE, The NFLG, et al.. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol 2019;76:1035\u201348. https:\/\/doi.org\/10.1001\/jamaneurol.2019.1534.","DOI":"10.1001\/jamaneurol.2019.1534"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_032","doi-asserted-by":"crossref","unstructured":"Disanto, G, Barro, C, Benkert, P, Naegelin, Y, Schadelin, S, Giardiello, A, et al.. Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol 2017;81:857\u201370. https:\/\/doi.org\/10.1002\/ana.24954.","DOI":"10.1002\/ana.24954"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_033","doi-asserted-by":"crossref","unstructured":"Gaetani, L, Hoglund, K, Parnetti, L, Pujol-Calderon, F, Becker, B, Eusebi, P, et al.. A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation. Alzheimers Res Ther 2018;10:8. https:\/\/doi.org\/10.1186\/s13195-018-0339-1.","DOI":"10.1186\/s13195-018-0339-1"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_034","doi-asserted-by":"crossref","unstructured":"Coppens, S, Lehmann, S, Hopley, C, Hirtz, C. Neurofilament-light, a promising biomarker: analytical, metrological and clinical challenges. Int J Mol Sci 2023;24. https:\/\/doi.org\/10.3390\/ijms241411624.","DOI":"10.3390\/ijms241411624"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_035","doi-asserted-by":"crossref","unstructured":"Forgrave, LM, Ma, M, Best, JR, DeMarco, ML. The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer\u2019s disease, frontotemporal dementia, and amyotrophic lateral sclerosis: a systematic review and meta-analysis. Alzheimers Dement (Amst) 2019;11:730\u201343. https:\/\/doi.org\/10.1016\/j.dadm.2019.08.009.","DOI":"10.1016\/j.dadm.2019.08.009"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_036","doi-asserted-by":"crossref","unstructured":"Arslan, B, Zetterberg, H. Neurofilament light chain as neuronal injury marker\u00a0\u2013\u00a0what is needed to facilitate implementation in clinical laboratory practice? Clin Chem Lab Med 2023;61:1140\u20139. https:\/\/doi.org\/10.1515\/cclm-2023-0036.","DOI":"10.1515\/cclm-2023-0036"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_037","doi-asserted-by":"crossref","unstructured":"Sheth, U, Harrison, R, Ferber, K, Rosenbaugh, EG, Bevis, A, Khillan, R, et al.. Measuring neurofilament light in human plasma and cerebrospinal fluid: a comparison of five analytical immunoassays. Clin Chem Lab Med 2025;64:410\u201320. https:\/\/doi.org\/10.1515\/cclm-2025-0610.","DOI":"10.1515\/cclm-2025-0610"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_038","doi-asserted-by":"crossref","unstructured":"Benkert, P, Meier, S, Schaedelin, S, Manouchehrinia, A, Yaldizli, O, Maceski, A, et al.. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol 2022;21:246\u201357. https:\/\/doi.org\/10.1016\/s1474-4422(22)00009-6.","DOI":"10.1016\/S1474-4422(22)00009-6"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_039","doi-asserted-by":"crossref","unstructured":"Simren, J, Andreasson, U, Gobom, J, Suarez Calvet, M, Borroni, B, Gillberg, C, et al.. Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5\u2013-90 years. Brain Commun 2022;4:fcac174. https:\/\/doi.org\/10.1093\/braincomms\/fcac174.","DOI":"10.1093\/braincomms\/fcac174"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_040","doi-asserted-by":"crossref","unstructured":"Ashton, NJ, Suarez-Calvet, M, Karikari, TK, Lantero-Rodriguez, J, Snellman, A, Sauer, M, et al.. Effects of pre-analytical procedures on blood biomarkers for Alzheimer\u2019s pathophysiology, glial activation, and neurodegeneration. Alzheimers Dement (Amst) 2021;13:e12168. https:\/\/doi.org\/10.1002\/dad2.12168.","DOI":"10.1002\/dad2.12168"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_041","doi-asserted-by":"crossref","unstructured":"Rubsamen, N, Willemse, EAJ, Leppert, D, Wiendl, H, Nauck, M, Karch, A, et al.. A method to combine neurofilament light measurements from blood serum and plasma in clinical and population-based studies. Front Neurol 2022;13:894119. https:\/\/doi.org\/10.3389\/fneur.2022.894119.","DOI":"10.3389\/fneur.2022.894119"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_042","doi-asserted-by":"crossref","unstructured":"Barro, C, Chitnis, T, Weiner, HL. Blood neurofilament light: a critical review of its application to neurologic disease. Ann Clin Transl Neurol 2020;7:2508\u201323. https:\/\/doi.org\/10.1002\/acn3.51234.","DOI":"10.1002\/acn3.51234"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_043","doi-asserted-by":"crossref","unstructured":"Cordts, I, Fuetterer, C, Wachinger, A, von Heynitz, R, Kessler, T, Freigang, M, et al.. Long-term dynamics of CSF and serum neurofilament light chain in adult patients with 5q spinal muscular atrophy treated with nusinersen. Neurology 2025;104:e213371. https:\/\/doi.org\/10.1212\/wnl.0000000000213371.","DOI":"10.1212\/WNL.0000000000213371"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_044","doi-asserted-by":"crossref","unstructured":"Ramanathan, M. Non-neurological factors associated with serum neurofilament levels in the United\u00a0States population. Ann Clin Transl Neurol 2024;11:1347\u201358. https:\/\/doi.org\/10.1002\/acn3.52054.","DOI":"10.1002\/acn3.52054"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_045","doi-asserted-by":"crossref","unstructured":"Kaeser, SA, Lehallier, B, Thinggaard, M, Hasler, LM, Apel, A, Bergmann, C, et al.. A neuronal blood marker is associated with mortality in old age. Nat Aging 2021;1:218\u201325. https:\/\/doi.org\/10.1038\/s43587-021-00028-4.","DOI":"10.1038\/s43587-021-00028-4"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_046","doi-asserted-by":"crossref","unstructured":"Khalil, M, Pirpamer, L, Hofer, E, Voortman, MM, Barro, C, Leppert, D, et al.. Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nat Commun 2020;11:812. https:\/\/doi.org\/10.1038\/s41467-020-14612-6.","DOI":"10.1038\/s41467-020-14612-6"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_047","doi-asserted-by":"crossref","unstructured":"Hermesdorf, M, Leppert, D, Maceski, A, Benkert, P, Wellmann, J, Wiendl, H, et al.. Longitudinal analyses of serum neurofilament light and associations with obesity indices and bioelectrical impedance parameters. Sci Rep 2022;12:15863. https:\/\/doi.org\/10.1038\/s41598-022-20398-y.","DOI":"10.1038\/s41598-022-20398-y"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_048","doi-asserted-by":"crossref","unstructured":"Manouchehrinia, A, Piehl, F, Hillert, J, Kuhle, J, Alfredsson, L, Olsson, T, et al.. Confounding effect of blood volume and body mass index on blood neurofilament light chain levels. Ann Clin Transl Neurol 2020;7:139\u201343. https:\/\/doi.org\/10.1002\/acn3.50972.","DOI":"10.1002\/acn3.50972"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_049","doi-asserted-by":"crossref","unstructured":"Koini, M, Pirpamer, L, Hofer, E, Buchmann, A, Pinter, D, Ropele, S, et al.. Factors influencing serum neurofilament light chain levels in normal aging. Aging (Albany NY) 2021;13:25729\u201338. https:\/\/doi.org\/10.18632\/aging.203790.","DOI":"10.18632\/aging.203790"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_050","doi-asserted-by":"crossref","unstructured":"Lu, JD, Kadier, K, Dilixiati, D, Qiao, B, Nuer, R, Zebibula, A, et al.. Association between serum neurofilament light chain levels and chronic kidney disease: a cross-sectional population-based study from the National Health and Nutrition Examination Survey (2013\u2013-2014 cycle). Ren Fail 2024;46:2427178. https:\/\/doi.org\/10.1080\/0886022x.2024.2427178.","DOI":"10.1080\/0886022X.2024.2427178"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_051","doi-asserted-by":"crossref","unstructured":"Peng, H, Liang, Z, Huang, B, Zhang, S, Yang, Y. Negative association of serum neurofilament light chain with estimated glomerular filtration rate levels and the impact of gender. Front Neurol 2024;15:1457984. https:\/\/doi.org\/10.3389\/fneur.2024.1457984.","DOI":"10.3389\/fneur.2024.1457984"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_052","doi-asserted-by":"crossref","unstructured":"Liu, J, Zhang, Y. Serum neurofilament light chain: a novel biomarker for cardiovascular diseases in individuals without hypertension. Sci Rep 2024;14:26117. https:\/\/doi.org\/10.1038\/s41598-024-77446-y.","DOI":"10.1038\/s41598-024-77446-y"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_053","doi-asserted-by":"crossref","unstructured":"Maalmi, H, Strom, A, Petrera, A, Hauck, SM, Strassburger, K, Kuss, O, et al.. Serum neurofilament light chain: a novel biomarker for early diabetic sensorimotor polyneuropathy. Diabetologia 2023;66:579\u201389. https:\/\/doi.org\/10.1007\/s00125-022-05846-8.","DOI":"10.1007\/s00125-022-05846-8"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_054","doi-asserted-by":"crossref","unstructured":"Akamine, S, Marutani, N, Kanayama, D, Gotoh, S, Maruyama, R, Yanagida, K, et al.. Renal function is associated with blood neurofilament light chain level in older adults. Sci Rep 2020;10:20350. https:\/\/doi.org\/10.1038\/s41598-020-76990-7.","DOI":"10.1038\/s41598-020-76990-7"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_055","doi-asserted-by":"crossref","unstructured":"Sjolin, K, Aulin, J, Wallentin, L, Eriksson, N, Held, C, Kultima, K, et al.. Serum neurofilament light chain in patients with atrial fibrillation. J\u00a0Am Heart Assoc 2022;11:e025910. https:\/\/doi.org\/10.1161\/jaha.122.025910.","DOI":"10.1161\/JAHA.122.025910"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_056","doi-asserted-by":"crossref","unstructured":"Fridman, V, Sillau, S, Ritchie, A, Bockhorst, J, Coughlan, C, Araya, P, et al.. Plasma neurofilament light chain concentrations are elevated in youth-onset type 2 diabetes and associated with neuropathy. J\u00a0Peripher Nerv Syst 2023;28:460\u201370. https:\/\/doi.org\/10.1111\/jns.12575.","DOI":"10.1111\/jns.12575"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_057","doi-asserted-by":"crossref","unstructured":"Silva, AS, Guimaraes, J, Sousa, C, Mendonca, L, Soares-Dos-Reis, R, Mendonca, T, et al.. Metabolic syndrome parameters and multiple sclerosis disease outcomes: a Portuguese cross-sectional study. Mult Scler Relat Disord 2023;69:104370. https:\/\/doi.org\/10.1016\/j.msard.2022.104370.","DOI":"10.1016\/j.msard.2022.104370"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_058","doi-asserted-by":"crossref","unstructured":"Harp, C, Thanei, GA, Jia, X, Kuhle, J, Leppert, D, Schaedelin, S, et al.. Development of an age-adjusted model for blood neurofilament light chain. Ann Clin Transl Neurol 2022;9:444\u201353. https:\/\/doi.org\/10.1002\/acn3.51524.","DOI":"10.1002\/acn3.51524"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_059","doi-asserted-by":"crossref","unstructured":"Lanz, TA, Ruprecht, K, Somps, CJ, Gopfert, JC, Kam-Thong, T, Tekle, F, et al.. Longitudinal evaluation of serum neurofilament light levels in normal healthy volunteers: defining a threshold of concern. J\u00a0Neurol 2025;272:512. https:\/\/doi.org\/10.1007\/s00415-025-13246-2.","DOI":"10.1007\/s00415-025-13483-5"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_060","doi-asserted-by":"crossref","unstructured":"Bergman, J, Dring, A, Zetterberg, H, Blennow, K, Norgren, N, Gilthorpe, J, et al.. Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS. Neurol Neuroimmunol Neuroinflamm 2016;3:e271. https:\/\/doi.org\/10.1212\/nxi.0000000000000271.","DOI":"10.1212\/NXI.0000000000000271"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_061","doi-asserted-by":"crossref","unstructured":"Fox, RJ, Cree, BAC, de Seze, J, Gold, R, Hartung, HP, Jeffery, D, et al.. Temporal relationship between serum neurofilament light chain and radiologic disease activity in patients with multiple sclerosis. Neurology 2024;102:e209357. https:\/\/doi.org\/10.1212\/wnl.0000000000209357.","DOI":"10.1212\/WNL.0000000000209357"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_062","doi-asserted-by":"crossref","unstructured":"Freedman, MS, Gnanapavan, S, Booth, RA, Calabresi, PA, Khalil, M, Kuhle, J, et al.. Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management. EBioMedicine 2024;101:104970. https:\/\/doi.org\/10.1016\/j.ebiom.2024.104970.","DOI":"10.1016\/j.ebiom.2024.104970"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_063","doi-asserted-by":"crossref","unstructured":"Kuhle, J, Kropshofer, H, Haering, DA, Kundu, U, Meinert, R, Barro, C, et al.. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology 2019;92:e1007\u201315. https:\/\/doi.org\/10.1212\/wnl.0000000000007032.","DOI":"10.1212\/WNL.0000000000007032"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_064","doi-asserted-by":"crossref","unstructured":"Bittner, S, Steffen, F, Uphaus, T, Muthuraman, M, Fleischer, V, Salmen, A, et al.. Clinical implications of serum neurofilament in newly diagnosed MS patients: a longitudinal multicentre cohort study. EBioMedicine 2020;56:102807. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102807.","DOI":"10.1016\/j.ebiom.2020.102807"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_065","doi-asserted-by":"crossref","unstructured":"Valentino, P, Marnetto, F, Martire, S, Malucchi, S, Bava, CI, Popovic, M, et al.. Serum neurofilament light chain levels in healthy individuals: a proposal of cut-off values for use in multiple sclerosis clinical practice. Mult Scler Relat Disord 2021;54:103090. https:\/\/doi.org\/10.1016\/j.msard.2021.103090.","DOI":"10.1016\/j.msard.2021.103090"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_066","doi-asserted-by":"crossref","unstructured":"Vermunt, L, Otte, M, Verberk, IMW, Killestein, J, Lemstra, AW, van der Flier, WM, et al.. Age- and disease-specific reference values for neurofilament light presented in an online interactive support interface. Ann Clin Transl Neurol 2022;9:1832\u20137. https:\/\/doi.org\/10.1002\/acn3.51676.","DOI":"10.1002\/acn3.51676"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_067","doi-asserted-by":"crossref","unstructured":"Nicolella, V, Varelli, M, Fasano, S, Sirica, R, Polito, C, Saviano, A, et al.. Clinical application of age-derived cut-offs for plasma neurofilament light chain in multiple sclerosis. J\u00a0Neurol 2025;272:495. https:\/\/doi.org\/10.1007\/s00415-025-13223-9.","DOI":"10.1007\/s00415-025-13223-9"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_068","doi-asserted-by":"crossref","unstructured":"Bjornevik, K, Munger, KL, Cortese, M, Barro, C, Healy, BC, Niebuhr, DW, et al.. Serum neurofilament light chain levels in patients with presymptomatic multiple sclerosis. JAMA Neurol 2020;77:58\u201364. https:\/\/doi.org\/10.1001\/jamaneurol.2019.3238.","DOI":"10.1001\/jamaneurol.2019.3238"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_069","doi-asserted-by":"crossref","unstructured":"Jons, D, Zetterberg, H, Bistrom, M, Alonso-Magdalena, L, Gunnarsson, M, Vrethem, M, et al.. Axonal injury in asymptomatic individuals preceding onset of multiple sclerosis. Ann Clin Transl Neurol 2022;9:882\u20137. https:\/\/doi.org\/10.1002\/acn3.51568.","DOI":"10.1002\/acn3.51568"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_070","doi-asserted-by":"crossref","unstructured":"Abdelhak, A, Cerono, G, Sheikhzadeh, F, Harroud, A, Ning, K, Zamecnik, CR, et al.. Myelin injury precedes axonal injury and symptomatic onset in multiple sclerosis. Nat Med 2025;32:362\u20138. https:\/\/doi.org\/10.1038\/s41591-025-04014-w.","DOI":"10.1038\/s41591-025-04014-w"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_071","doi-asserted-by":"crossref","unstructured":"Rival, M, Thouvenot, E, Du Trieu de Terdonck, L, Laurent-Chabalier, S, Demattei, C, Uygunoglu, U, et al.. Neurofilament light chain levels are predictive of clinical conversion in radiologically isolated syndrome. Neurol Neuroimmunol Neuroinflamm 2023;10. https:\/\/doi.org\/10.1212\/nxi.0000000000200044.","DOI":"10.1212\/NXI.0000000000200044"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_072","doi-asserted-by":"crossref","unstructured":"Fissolo, N, Schaedelin, S, Villar, LM, Lunemann, JD, Correale, J, Rejdak, K, et al.. Prognostic factors for multiple sclerosis symptoms in radiologically isolated syndrome. JAMA Neurol 2025;82:722\u201333. https:\/\/doi.org\/10.1001\/jamaneurol.2025.1481.","DOI":"10.1001\/jamaneurol.2025.1481"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_073","doi-asserted-by":"crossref","unstructured":"Monreal, E, Fernandez-Velasco, JI, Alvarez-Lafuente, R, Sainz de la Maza, S, Garcia-Sanchez, MI, Llufriu, S, et al.. Serum biomarkers at disease onset for personalized therapy in multiple sclerosis. Brain 2024;147:4084\u201393. https:\/\/doi.org\/10.1093\/brain\/awae260.","DOI":"10.1093\/brain\/awae260"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_074","doi-asserted-by":"crossref","unstructured":"Rotstein, D, Montalban, X. Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat Rev Neurol 2019;15:287\u2013300. https:\/\/doi.org\/10.1038\/s41582-019-0170-8.","DOI":"10.1038\/s41582-019-0170-8"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_075","doi-asserted-by":"crossref","unstructured":"Delcoigne, B, Manouchehrinia, A, Barro, C, Benkert, P, Michalak, Z, Kappos, L, et al.. Blood neurofilament light levels segregate treatment effects in multiple sclerosis. Neurology 2020;94:e1201\u201312. https:\/\/doi.org\/10.1212\/wnl.0000000000009097.","DOI":"10.1212\/WNL.0000000000009097"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_076","doi-asserted-by":"crossref","unstructured":"Bava, CI, Valentino, P, Malucchi, S, Bottero, R, Martire, S, Sapio, AD, et al.. Prevalence of elevated sNFL in a real-world setting: results on 908 patients with different multiple sclerosis types and treatment conditions. Mult Scler Relat Disord 2024;88:105748. https:\/\/doi.org\/10.1016\/j.msard.2024.105748.","DOI":"10.1016\/j.msard.2024.105748"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_077","doi-asserted-by":"crossref","unstructured":"Malucchi, S, Bava, CI, Valentino, P, Martire, S, Lo, RM, Bertolotto, A, et al.. In multiple sclerosis patients a single serum neurofilament light chain (sNFL) dosage is strongly associated with 12\u00a0months outcome: data from a real-life clinical setting. J\u00a0Neurol 2024;271:7494\u2013501. https:\/\/doi.org\/10.1007\/s00415-024-12701-w.","DOI":"10.1007\/s00415-024-12701-w"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_078","doi-asserted-by":"crossref","unstructured":"Cerqueira, JJ, Berthele, A, Cree, BAC, Filippi, M, Pardo, G, Pearson, OR, et al.. Long-term treatment with ocrelizumab in patients with early-stage relapsing MS: nine-year data from the OPERA studies open-label extension. Neurology 2025;104:e210142. https:\/\/doi.org\/10.1212\/wnl.0000000000210142.","DOI":"10.1212\/WNL.0000000000210142"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_079","doi-asserted-by":"crossref","unstructured":"He, A, Merkel, B, Brown, JWL, Zhovits Ryerson, L, Kister, I, Malpas, CB, et al.. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol 2020;19:307\u201316. https:\/\/doi.org\/10.1016\/s1474-4422(20)30067-3.","DOI":"10.1016\/S1474-4422(20)30067-3"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_080","doi-asserted-by":"crossref","unstructured":"Spelman, T, Magyari, M, Piehl, F, Svenningsson, A, Rasmussen, PV, Kant, M, et al.. Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies. JAMA Neurol 2021;78:1197\u2013204. https:\/\/doi.org\/10.1001\/jamaneurol.2021.2738.","DOI":"10.1001\/jamaneurol.2021.2738"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_081","doi-asserted-by":"crossref","unstructured":"Iaffaldano, P, Lucisano, G, Caputo, F, Paolicelli, D, Patti, F, Zaffaroni, M, et al.. Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. Ther Adv Neurol Disord 2021;14:17562864211019574. https:\/\/doi.org\/10.1177\/17562864211019574.","DOI":"10.1177\/17562864211019574"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_082","doi-asserted-by":"crossref","unstructured":"Bar-Or, A, Thanei, GA, Harp, C, Bernasconi, C, Bonati, U, Cross, AH, et al.. Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials. EBioMedicine 2023;93:104662. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104662.","DOI":"10.1016\/j.ebiom.2023.104662"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_083","doi-asserted-by":"crossref","unstructured":"Benkert, P, Maleska Maceski, A, Schaedelin, S, Oechtering, J, Zadic, A, Vilchez Gomez, JF, et al.. Serum glial fibrillary acidic protein and neurofilament light chain levels reflect different mechanisms of disease progression under B-Cell depleting treatment in multiple sclerosis. Ann Neurol 2024;97:104\u201315. https:\/\/doi.org\/10.1002\/ana.27096.","DOI":"10.1002\/ana.27096"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_084","doi-asserted-by":"crossref","unstructured":"Janiaud, P, Zecca, C, Salmen, A, Benkert, P, Schadelin, S, Orleth, A, et al.. MultiSCRIPT-Cycle 1-a pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in multiple sclerosis: a study protocol for a randomized clinical trial. Trials 2024;25:607. https:\/\/doi.org\/10.1186\/s13063-024-08454-6.","DOI":"10.1186\/s13063-024-08454-6"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_085","doi-asserted-by":"crossref","unstructured":"Yaldizli, O, Benkert, P, Achtnichts, L, Bar-Or, A, Bohner-Lang, V, Bridel, C, et al.. Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in multiple sclerosis: a modified Delphi study. Mult Scler 2025;31:932\u201343. https:\/\/doi.org\/10.1177\/13524585251335466.","DOI":"10.1177\/13524585251335466"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_086","doi-asserted-by":"crossref","unstructured":"Fissolo, N, Pignolet, B, Rio, J, Vermersch, P, Ruet, A, deSeze, J, et al.. Serum neurofilament levels and PML risk in patients with multiple sclerosis treated with natalizumab. Neurol Neuroimmunol Neuroinflamm 2021;8. https:\/\/doi.org\/10.1212\/nxi.0000000000001003.","DOI":"10.1212\/NXI.0000000000001003"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_087","doi-asserted-by":"crossref","unstructured":"Dalla Costa, G, Martinelli, V, Moiola, L, Sangalli, F, Colombo, B, Finardi, A, et al.. Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients. Ann Neurol 2019;85:606\u201310. https:\/\/doi.org\/10.1002\/ana.25437.","DOI":"10.1002\/ana.25437"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_088","doi-asserted-by":"crossref","unstructured":"Akgun, K, Kretschmann, N, Haase, R, Proschmann, U, Kitzler, HH, Reichmann, H, et al.. Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS. Neurol Neuroimmunol Neuroinflamm 2019;6:e555. https:\/\/doi.org\/10.1212\/nxi.0000000000000555.","DOI":"10.1212\/NXI.0000000000000555"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_089","doi-asserted-by":"crossref","unstructured":"Fung, WH, Wessels, MHJ, Coerver, EME, de Beukelaar, J, Bouvy, WH, Canta, LR, et al.. Reliability of serum neurofilament light and glial fibrillary acidic protein for detecting disease activity upon discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS). J\u00a0Neurol 2025;272:530. https:\/\/doi.org\/10.1007\/s00415-025-13231-9.","DOI":"10.1007\/s00415-025-13231-9"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_090","doi-asserted-by":"crossref","unstructured":"Proschmann, U, Inojosa, H, Akgun, K, Ziemssen, T. Natalizumab pharmacokinetics and -dynamics and serum neurofilament in patients with multiple sclerosis. Front Neurol 2021;12:650530. https:\/\/doi.org\/10.3389\/fneur.2021.650530.","DOI":"10.3389\/fneur.2021.650530"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_091","doi-asserted-by":"crossref","unstructured":"Disanto, G, Ripellino, P, Riccitelli, GC, Sacco, R, Scotti, B, Fucili, A, et al.. De-escalating rituximab dose results in stability of clinical, radiological, and serum neurofilament levels in multiple sclerosis. Mult Scler 2021;27:1230\u20139. https:\/\/doi.org\/10.1177\/1352458520952036.","DOI":"10.1177\/1352458520952036"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_092","doi-asserted-by":"crossref","unstructured":"Valentino, P, Malucchi, S, Martire, S, Bava, CI, Capobianco, MA, Bertolotto, A. sNFL applicability as additional monitoring tool in natalizumab extended interval dosing regimen for RRMS patients. Mult Scler Relat Disord 2022;67:104176. https:\/\/doi.org\/10.1016\/j.msard.2022.104176.","DOI":"10.1016\/j.msard.2022.104176"},{"key":"2026091512595688619_j_cclm-2025-1743_ref_093","doi-asserted-by":"crossref","unstructured":"Montalban, X, Lebrun-Frenay, C, Oh, J, Arrambide, G, Moccia, M, Pia Amato, M, et al.. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol 2025;24:850\u201365. https:\/\/doi.org\/10.1016\/s1474-4422(25)00270-4.","DOI":"10.1016\/S1474-4422(25)00270-4"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-1743\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-1743\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:00:45Z","timestamp":1789477245000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-1743\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":93,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,3,13]]},"published-print":{"date-parts":[[2026,8,24]]}},"alternative-id":["10.1515\/cclm-2025-1743"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2025-1743","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]}}}